Comment
doi: 10.1016/S2468-1253(23)00109-7.
Semaglutide in NASH-related cirrhosis: still a long way to go?
Affiliations
- PMID: 37453428
- DOI: 10.1016/S2468-1253(23)00109-7
Item in Clipboard
Comment
Semaglutide in NASH-related cirrhosis: still a long way to go?
Lancet Gastroenterol Hepatol.
2023 Aug.
No abstract available
Conflict of interest statement
We declare no competing interests.
Comment in
-
Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.Lancet Gastroenterol Hepatol. 2023 Aug;8(8):694-695. doi: 10.1016/S2468-1253(23)00160-7. Lancet Gastroenterol Hepatol. 2023. PMID: 37453429 No abstract available.
Comment on
-
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36934740 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
